Conditions: Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 27
Healthy volunteers: no

Brief summary:
This is a multicenter, single-arm study for safety and efficacy.

Detailed description:

Arms:
arm 1: 3 capsules of 120 mg each, administered twice a day (once in the morning and once in the evening - total daily dose of 720 mg) in continuous 4-week cycles

Interventions: intervention 1: Tivantinib (ARQ 197)
Intervention descriptions: intervention 1: Capsule, 120 mg, BID (360 mg), approximately 112 days

Protocol document: